Beijing Zhihe Biopharma

Beijing Zhihe Biopharma is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of innovative biologics for cancer immunotherapy. The company utilizes its proprietary Z-Body bispecific antibody platform to engineer multi-functional therapeutic candidates that target the complex tumor microenvironment. Its lead asset, ZH-001, is a bifunctional fusion protein targeting PD-L1 and TGF-beta, currently undergoing Phase 1/2 clinical trials for advanced solid tumors. The pipeline also includes antibody-drug conjugates and bispecific antibodies targeting pathways such as Claudin 18.2 and 4-1BB. Supported by leading investors like IDG Capital and SDIC Unity Capital, Zhihe Biopharma aims to address significant unmet needs in oncology through precision medicine and advanced antibody engineering.